Ropinirole for restless legs syndrome: A placebo-controlled crossover trial

C. H. Adler; R. A. Hauser; K. Sethi; J. N. Caviness; L. Marlor; W. M. Anderson; J. G. Hentz

doi:10.1212/01.WNL.0000120672.94060.F1

Ropinirole for restless legs syndrome: A placebo-controlled crossover trial

C. H. Adler, R. A. Hauser, K. Sethi, J. N. Caviness, L. Marlor, W. M. Anderson, J. G. Hentz

Research output: Contribution to journal › Article › peer-review

92 Scopus citations

Abstract

The authors performed a double-blind, placebo-controlled, crossover study of ropinirole (0.5 to 6.0 mg/day) for restless legs syndrome (RLS). The RLS Rating Scale score improved (p < 0.001) from a mean (SD) of 25 (7) during placebo treatment to 13 (12) during ropinirole treatment. Eight of the 22 patients had complete resolution of symptoms on ropinirole. Adverse events included nausea and dizziness. Ropinirole was effective and well tolerated for treating the symptoms of RLS.

Original language	English (US)
Pages (from-to)	1405-1407
Number of pages	3
Journal	Neurology
Volume	62
Issue number	8
DOIs	https://doi.org/10.1212/01.WNL.0000120672.94060.F1
State	Published - Apr 27 2004
Externally published	Yes

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1212/01.WNL.0000120672.94060.F1

Cite this

@article{03d3128cdebe47e6b75eaf0b5628e50b,

title = "Ropinirole for restless legs syndrome: A placebo-controlled crossover trial",

abstract = "The authors performed a double-blind, placebo-controlled, crossover study of ropinirole (0.5 to 6.0 mg/day) for restless legs syndrome (RLS). The RLS Rating Scale score improved (p < 0.001) from a mean (SD) of 25 (7) during placebo treatment to 13 (12) during ropinirole treatment. Eight of the 22 patients had complete resolution of symptoms on ropinirole. Adverse events included nausea and dizziness. Ropinirole was effective and well tolerated for treating the symptoms of RLS.",

author = "Adler, {C. H.} and Hauser, {R. A.} and K. Sethi and Caviness, {J. N.} and L. Marlor and Anderson, {W. M.} and Hentz, {J. G.}",

year = "2004",

month = apr,

day = "27",

doi = "10.1212/01.WNL.0000120672.94060.F1",

language = "English (US)",

volume = "62",

pages = "1405--1407",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "8",

}

TY - JOUR

T1 - Ropinirole for restless legs syndrome

T2 - A placebo-controlled crossover trial

AU - Adler, C. H.

AU - Hauser, R. A.

AU - Sethi, K.

AU - Caviness, J. N.

AU - Marlor, L.

AU - Anderson, W. M.

AU - Hentz, J. G.

PY - 2004/4/27

Y1 - 2004/4/27

N2 - The authors performed a double-blind, placebo-controlled, crossover study of ropinirole (0.5 to 6.0 mg/day) for restless legs syndrome (RLS). The RLS Rating Scale score improved (p < 0.001) from a mean (SD) of 25 (7) during placebo treatment to 13 (12) during ropinirole treatment. Eight of the 22 patients had complete resolution of symptoms on ropinirole. Adverse events included nausea and dizziness. Ropinirole was effective and well tolerated for treating the symptoms of RLS.

AB - The authors performed a double-blind, placebo-controlled, crossover study of ropinirole (0.5 to 6.0 mg/day) for restless legs syndrome (RLS). The RLS Rating Scale score improved (p < 0.001) from a mean (SD) of 25 (7) during placebo treatment to 13 (12) during ropinirole treatment. Eight of the 22 patients had complete resolution of symptoms on ropinirole. Adverse events included nausea and dizziness. Ropinirole was effective and well tolerated for treating the symptoms of RLS.

UR - http://www.scopus.com/inward/record.url?scp=1942537789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1942537789&partnerID=8YFLogxK

U2 - 10.1212/01.WNL.0000120672.94060.F1

DO - 10.1212/01.WNL.0000120672.94060.F1

M3 - Article

C2 - 15111683

AN - SCOPUS:1942537789

SN - 0028-3878

VL - 62

SP - 1405

EP - 1407

JO - Neurology

JF - Neurology

IS - 8

ER -

Ropinirole for restless legs syndrome: A placebo-controlled crossover trial

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this